WASHINGTON — Pfizer and BioNTech are partnering with a Brazilian biopharmaceutical company to begin producing doses of their COVID-19 vaccine exclusively for distribution within Latin America, significantly boosting vaccine access in a region that has struggled to secure supply, the company said Thursday.
The partnership with Eurofarma Laboratórios SA could produce more than 100 million doses each year for use across the region once they are “at full operational capacity,” a Pfizer spokesperson said.
Pfizer’s coronavirus vaccine, officially named Comirnaty, was the first to receive full use approval from the U.S. Food and Drug Administration this week.
